The U.S. GAO has released a new report on international pricing comparisons, analyzing the prices for 20 brand-name drugs in the U.S. for 2020 and comparing them to the publicly available prices for the same drugs in Australia, Canada, and France.

The GAO analyzed 2020 price data for a non-generalizable sample of 41 brand-name drugs among those with the highest expenditures and use in the U.S. Medicare Part D program in 2017. Twenty of these drugs had price data available in all four countries.

U.S. retail level prices were 2 to 4 times higher than prices in the comparison countries. However, clouding this comparison are the rebates and confidential discounts offered on some drugs.

The study also provides a comprehensive summary of the prescription drug coverage and pricing strategies across all four countries, as well as an in-depth overview of the drug supply chain and relevant price points.

Comments